Stockreport

JPM26: 2025 a “breakout year” for rare disease biotechs [Yahoo! Finance]

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF Several rare disease biotechs hailed commercial successes in 2025 as marking a turning point in the sector's maturation, despite lingering reliance on single lead asset [Read more]